PSMB3 Antibody

What is PSMB3 and why is it important in cellular research?

PSMB3 (Proteasome 20S Subunit Beta 3) is a non-catalytic component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits . PSMB3 plays crucial roles in cellular proteostasis through:

• Participation in the ATP-dependent degradation of ubiquitinated proteins when associated with 19S regulatory particles to form the 26S proteasome

• Maintaining protein homeostasis by removing misfolded or damaged proteins

• Contributing to ubiquitin-independent protein degradation when associated with PA200 or PA28

• Supporting essential cellular pathways including spermatogenesis and MHC class I antigen presentation

Diseases associated with PSMB3 include Cystic Fibrosis and Parkinson's Disease, making it a valuable target for neurological and immunological research .

What types of PSMB3 antibodies are commonly used in research?

Several types of PSMB3 antibodies are available for research purposes, each with specific advantages depending on the experimental application:

Polyclonal Antibodies:

• Rabbit polyclonal antibodies (e.g., 15983-1-AP) that recognize multiple epitopes of PSMB3

• Generated through immunization with PSMB3 fusion proteins or recombinant proteins

• Show reactivity with human, mouse, and rat samples

Recombinant Proteins for Antibody Production:

• GST-fusion proteins: GST-PSMB3 expressed in E. coli BL21 (DE3) cells and purified by glutathione-affinity chromatography

• His-tagged proteins: Human PSMB3 protein (AA 1-246) with His tag, expressed in E. coli with >95% purity

Host Species and Tags:

• Host species include rabbit (most common)

• Available tags include His tag, GST tag

The selection of antibody type should be based on the specific experimental requirements and target species.

What applications are PSMB3 antibodies validated for?

PSMB3 antibodies have been validated for multiple applications based on experimental data:

These applications enable researchers to study PSMB3 expression, localization, and interactions within cellular contexts.

What are the recommended storage and handling conditions for PSMB3 antibodies?

Proper storage and handling of PSMB3 antibodies are critical for maintaining their activity and specificity:

Storage Conditions:

• Store antibodies at -20°C for long-term storage

• Most PSMB3 antibodies remain stable for one year after shipment when stored properly

• Aliquoting is generally unnecessary for -20°C storage of small volumes (e.g., 20μl)

• Some formulations may contain 0.1% BSA as a stabilizer

Buffer Composition:

• Typically supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

• Lyophilized formats may be stored in buffers containing 10 mM Hepes, 500 mM NaCl with 5% trehalose at pH 7.4

Reconstitution of Lyophilized Antibodies:

• Centrifuge the vial at 10,000 rpm for 1 minute

• Reconstitute at 200 μg/mL in sterile distilled water by gentle pipetting 2-3 times

• Avoid vortexing, which can damage antibody structure

• After reconstitution, antibodies may be stored at 2-8°C for up to 1 month under sterile conditions

Handling Precautions:

• Small volumes may occasionally become entrapped in the seal of the product vial during shipment and storage

• Working dilutions should be determined by the investigator for optimal results in specific experimental systems

What is the optimal protocol for using PSMB3 antibodies in Western blot experiments?

The following protocol is recommended for Western blot experiments with PSMB3 antibodies, based on validated research applications:

Sample Preparation:

• Prepare cell or tissue lysates using standard lysis buffers containing protease inhibitors

• Quantify protein concentration using Bradford or BCA assay

• Load 20-50 μg of total protein per lane depending on PSMB3 expression levels

Gel Electrophoresis and Transfer:

• Separate proteins on 12-15% SDS-PAGE gels (optimal for 23-27 kDa proteins)

• Transfer to PVDF or nitrocellulose membranes using standard wet or semi-dry transfer systems

Immunoblotting:

• Block membranes with 5% non-fat milk in TBST for 1 hour at room temperature

• Incubate with primary PSMB3 antibody at 1:1000-1:4000 dilution (optimize for your specific antibody) overnight at 4°C

• Wash 3× with TBST, 5 minutes each

• Incubate with HRP-conjugated secondary antibody (anti-rabbit IgG for most PSMB3 antibodies) at 1:5000 dilution for 1 hour at room temperature

• Wash 3× with TBST, 5 minutes each

• Develop using ECL substrate and image using a chemiluminescence detection system

Expected Results:

• PSMB3 appears as a band at 23-27 kDa

• Positive controls include Jurkat cells, HEK-293T cells, HeLa cells, and MCF-7 cells

This protocol has been successfully used to detect both recombinant and endogenous PSMB3 from different human cell lines and mouse/rat testis tissue .

How can researchers validate the specificity of PSMB3 antibodies?

Validating antibody specificity is crucial for ensuring reliable experimental results. For PSMB3 antibodies, consider these validation approaches:

Genetic Validation:

• Use CRISPR/Cas9 to knock out PSMB3 in cell lines

• Compare Western blot results between wild-type and knockout cells

• The specific band at 23-27 kDa should be absent in knockout cells

Recombinant Protein Controls:

• Run purified recombinant PSMB3 protein alongside cellular samples

• Verify that the antibody detects the recombinant protein at the expected molecular weight

• Compare with commercially available PSMB3 proteins like those expressed in E. coli (>95% purity)

Multiple Antibody Validation:

• Compare results from different PSMB3 antibodies targeting distinct epitopes

• Consistent detection patterns across antibodies suggest higher specificity

• Consider using both monoclonal and polyclonal antibodies for comprehensive validation

Peptide Competition Assay:

• Pre-incubate the antibody with excess purified PSMB3 protein or immunizing peptide

• In parallel, use the antibody without pre-incubation

• The specific signal should be significantly reduced or eliminated in the pre-incubation condition

Cross-reactivity Testing:

• Test the antibody on samples from different species (human, mouse, rat) if cross-reactivity is claimed

• Verify that detection patterns align with known evolutionary conservation of PSMB3

• Most PSMB3 antibodies show reactivity with human, mouse, and rat samples

These validation strategies ensure that experimental observations are due to specific detection of PSMB3 rather than non-specific interactions.

What dilutions and experimental conditions are recommended for different PSMB3 antibody applications?

Optimal dilutions and conditions vary by application. The following recommendations are based on validated experimental data:

Important Notes:

• It is recommended to titrate antibody concentrations for each new experimental system to obtain optimal results

• Sample-dependent variations may require adjustment of dilutions

• For reproducibility, maintain consistent antibody lots when possible

• Validation data galleries provided by manufacturers can guide appropriate dilution ranges for specific sample types

What cell lines and tissues are known to express PSMB3 at detectable levels?

PSMB3 is widely expressed in various cell types and tissues, making it accessible for study in multiple experimental systems:

Cell Lines with Validated PSMB3 Expression:

• Jurkat cells (human T lymphocyte)

• HEK-293T cells (human embryonic kidney)

• HeLa cells (human cervical cancer)

• MCF-7 cells (human breast cancer)

These cell lines have been experimentally verified to express PSMB3 at levels detectable by Western blotting, immunofluorescence, and other antibody-based methods.

Tissue Expression:

• Human liver tissue (validated for IHC applications)

• Mouse testis tissue (validated for Western blot)

• Rat testis tissue (validated for Western blot)

Expression Pattern Considerations:

• As a proteasome subunit, PSMB3 is expressed in most eukaryotic cells

• Expression levels may vary depending on cellular state and stress conditions

• PSMB3 is primarily localized in the cytoplasm and nucleus

• The proteasome is distributed throughout eukaryotic cells at high concentration

When designing experiments, these validated expression systems can serve as positive controls for PSMB3 detection.

What are the technical considerations for using PSMB3 antibodies in co-immunoprecipitation experiments?

Co-immunoprecipitation (Co-IP) with PSMB3 antibodies requires careful optimization to preserve protein-protein interactions within the proteasome complex:

Buffer Composition:

• Use mild lysis buffers to preserve native protein complexes (e.g., 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40 or 0.5% Triton X-100)

• Include protease inhibitors to prevent degradation during lysis and IP

• Consider adding ATP (1-5 mM) to stabilize the assembled proteasome complex

• Avoid harsh detergents like SDS that can disrupt protein-protein interactions

IP Protocol Optimization:

• Pre-clear lysates with protein A/G beads to reduce non-specific binding

• Incubate cleared lysates with PSMB3 antibody overnight at 4°C with gentle rotation

• Use protein A/G beads to capture antibody-protein complexes

• Perform extensive washing (4-5 times) with lysis buffer containing reduced detergent

• Elute complexes with gentle methods (e.g., low pH glycine buffer or competition with excess antigen)

Controls and Validation:

• Include IgG control from the same species as the PSMB3 antibody

• Perform reciprocal Co-IPs with antibodies against known interacting partners

• Validate interactions using orthogonal methods (e.g., proximity ligation assay)

Expected Co-Precipitating Proteins:

• Other proteasome subunits (PSMA1-7, PSMB1-7)

• Regulatory particles (19S, PA28, PA200)

• Ubiquitinated substrates

• Proteasome-associated proteins

Research has demonstrated that anti-PSMA3 and anti-PSMA5 sera can successfully recognize and immunoprecipitate native forms of both endogenous and overexpressed FLAG-tagged proteins , suggesting similar approaches may be effective for PSMB3.

How can PSMB3 antibodies be used to study proteasome dysfunction in neurodegenerative diseases?

PSMB3 antibodies provide valuable tools for investigating proteasome dysfunction in neurodegenerative diseases like Parkinson's Disease, which has been associated with PSMB3 :

Experimental Approaches:

• Comparative Expression Analysis:

  • Compare PSMB3 protein levels between control and diseased tissues/cells using Western blot

  • Quantify differences in proteasome subunit ratios that may indicate altered complex assembly

  • Correlate PSMB3 expression with disease progression markers

• Proteasome Activity Correlation:

  • Combine PSMB3 immunodetection with fluorogenic substrate assays for proteasome activity

  • Analyze whether changes in PSMB3 levels correlate with alterations in proteolytic activity

  • Determine if PSMB3 can serve as a biomarker for proteasome dysfunction

• Subcellular Localization Studies:

  • Use immunofluorescence to track PSMB3 localization in neurons from disease models

  • Analyze co-localization with protein aggregates characteristic of neurodegenerative diseases

  • Examine whether PSMB3 redistribution occurs during disease progression

• Interaction with Disease-Associated Proteins:

  • Perform Co-IP to investigate interactions between PSMB3 and disease-associated proteins

  • Study whether these interactions are altered in disease states

  • Determine if pathogenic proteins affect proteasome assembly or function

• Post-Translational Modification Analysis:

  • Investigate disease-specific post-translational modifications of PSMB3

  • Combine IP with mass spectrometry to identify modifications

  • Examine whether these modifications affect proteasome function

Disease Model Systems:

• Patient-derived iPSCs differentiated into neurons

• Transgenic mouse models of neurodegenerative diseases

• Cell lines expressing disease-associated mutations

• Primary neurons treated with disease-relevant stressors (e.g., oxidative stress, protein aggregation inducers)

This approach has significant potential for understanding how proteasome dysfunction contributes to disease pathogenesis and identifying potential therapeutic targets.

What methodologies can distinguish between PSMB3 and other proteasome subunits when using antibodies?

Distinguishing between different proteasome subunits is challenging due to structural similarities but critical for accurate research. Consider these methodological approaches:

Antibody Selection Strategy:

• Choose antibodies raised against unique regions of PSMB3 not conserved in other beta subunits

• Verify epitope specificity through sequence alignment analysis

• Prioritize antibodies validated against multiple proteasome subunits to confirm specificity

Cross-Reactivity Testing:

• Test PSMB3 antibodies against recombinant proteins of other proteasome subunits

• Perform Western blots with purified 20S proteasome and confirm band size specificity

• Include cell lysates overexpressing individual subunits as controls

2D Gel Electrophoresis Approach:

• Separate proteasome subunits by isoelectric point followed by molecular weight

• Perform Western blot with PSMB3 antibody

• Confirm spot identity by mass spectrometry

• Compare with 2D maps of proteasome complexes

Multi-Color Immunofluorescence:

• Co-stain with antibodies against PSMB3 and other subunits (e.g., PSMB5, PSMA1)

• Use spectrally distinct fluorophores for each subunit

• Analyze co-localization patterns and unique distribution profiles

Immunodepletion Strategy:

• Sequentially deplete cell lysates with antibodies against specific subunits

• Analyze remaining protein by Western blot

• Confirm specificity by the selective depletion of PSMB3 but not other subunits

Publications have identified several proteasome subunits frequently studied alongside PSMB3, including PSMB2, PSMB5, PSMA1, PSMB6, PSMA6, PSMB10, PSMA7, PSMB4, PSMB1, and PSMA2 . This information can guide the selection of appropriate controls for specificity testing.

What approaches can be used to study post-translational modifications of PSMB3 using antibodies?

Post-translational modifications (PTMs) of proteasome subunits like PSMB3 can significantly impact proteasome function. Here are methodological approaches to study PSMB3 PTMs:

IP-Based PTM Detection:

• Immunoprecipitate PSMB3 using validated antibodies

• Perform Western blot with modification-specific antibodies (phospho-, acetyl-, ubiquitin-specific)

• Alternatively, analyze IP products by mass spectrometry for comprehensive PTM mapping

• Compare PTM profiles under different cellular conditions or treatments

Phosphorylation Analysis:

• Treat cells with phosphatase inhibitors before lysis to preserve phosphorylation state

• Use Phos-tag™ acrylamide gels to enhance mobility shifts of phosphorylated PSMB3

• Perform 2D gel electrophoresis to separate different phosphorylation states

• Combine with phospho-specific antibodies if available for specific sites

Ubiquitination Detection:

• Express HA- or FLAG-tagged ubiquitin in cells

• Immunoprecipitate PSMB3 under denaturing conditions to disrupt non-covalent interactions

• Probe with anti-tag antibodies to detect ubiquitinated forms

• Use proteasome inhibitors to enhance detection of ubiquitinated species

Site-Directed Mutagenesis Approach:

• Identify potential PTM sites through bioinformatic prediction or mass spectrometry data

• Generate site-specific mutants (e.g., S→A for phosphorylation sites)

• Compare PTM patterns between wild-type and mutant PSMB3

• Assess functional consequences of preventing specific modifications

Targeted Mass Spectrometry:

• Immunoprecipitate PSMB3 using validated antibodies like anti-PSMB3 (15983-1-AP)

• Perform tryptic digestion followed by liquid chromatography-tandem mass spectrometry

• Use selected reaction monitoring (SRM) to quantify specific PTM-containing peptides

• Compare PTM abundance across experimental conditions

These approaches can be particularly valuable for understanding how PSMB3 modifications contribute to proteasome regulation in both normal and disease states, including conditions like Parkinson's Disease and Cystic Fibrosis that have been associated with PSMB3 .